Literature Cited

  • 1
    American Joint Committee for Cancer Staging and End Results Reporting: Manual for Staging of Cancer, 1978.
  • 2
    Auer G, Eriksson E, Azavedo E, Caspersson T, Wallgren A: Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans. Cancer Res 44: 394396, 1984.
  • 3
    Barlogie B, Johnson DA, Smallwood L, Raber MN, Maddox AM, Latreille J, Swartzendruber DE, Drewinko B: Prognostic implications of ploidy and proliferative activity in human solid tumours. Cancer Genet Cytogenet 6: 1728, 1982.
  • 4
    Barlogie B, Raber MN, Schuhmann J, Johnson TB, Drewinko, B, Swartzendruber DE, Göhde W, Andreeff M, Freireich E: Flow cytometry in clinical cancer research. Cancer Res 43: 39823997, 1983.
  • 5
    Blöndal T, Bengtsson A: Nuclear DNA measurements in squamous cell carcinoma of the lung: A guide for prognostic evaluation. Anticancer Res 1: 7986, 1981.
  • 6
    Braylan RC, Diamond LW, Powell ML, Harty-Golder B: Percentage of cells in the S-phase of the cell cycle in human lymphoma determined by flow cytometry. Cytometry 1: 171174, 1980.
  • 7
    Bunn PA, Krasnow St, Makuch RW, Schlam ML, Schechter GP: Flow cytometry analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: Clinical implications. Blood 59: 528535, 1982.
  • 8
    Bunn PA, Carney DN, Gazdar AF, Whang-Peng J, Matthews MJ: Diagnostic and biological implications of flow cytometric DNA content analysis in lung cancer. Cancer Res 43: 50265032, 1983.
  • 9
    Costa A, Bonadonna G, Villa E, Valagussa P, Silverstrini R: Labeling index as a prognostic marker in non-Hodgkin's lymphomas. J Natl Cancer Inst 66: 15, 1981.
  • 10
    Durie BGM, Salmon SE, Moon TE: Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55: 364372, 1980.
  • 11
    Fleischer W, Pelka R: A practical analysis of DNA-histograms with a laboratory computer In: Pulse-cytophotometry, Part III, LutzD (ed), Eureopean Press, Ghent, Belgium. 1978, pp. 137143.
  • 12
    Friedlander ML, Hedley DW, Taylor IW, Russell P, Coates AS, Tattersall MHN: Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 44: 397400, 1984.
  • 13
    Gustafson H, Tribukait B, Esposti PL: DNA profile and tumour progression in patients with superficial bladder tumours. Urol Res 10: 1318, 1982.
  • 14
    Haag D: Flow microfluorometric deoxyribonucleic acid (DNA) analysis supplementing routine histopathologic diagnosis of biopsy specimens. Lab Invest 42: 8590, 1980.
  • 15
    Hansson J, Tribukait B, Lewensohn R, Ringborg U: Flow cytofluorometric DNA analysis of metastases of human malignant melanomas. Anal Quant Cytol 4: 99104, 1982.
  • 16
    Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assn 53: 457481, 1958.
  • 17
    Laerum OD, Farsund I: Clinical application of flow cytometry: A review. Cytometry 2: 113, 1981.
  • 18
    Latreille J, Barlogie B, Johnston D: Drewinko B, Alexanian R: Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 59: 4351, 1982.
  • 19
    Livingstone RB, Ambus U, George SL, Freireich EJ, Hart JS: In vitro determination of thymidine- 3H labeling index in human solid tumors. Cancer Res 34: 13761380, 1974.
  • 20
    Meyer JS, Hixon B: Advanced stage and early relapse of breast carcinomas associated with high thymidine labelling indices. Cancer Res 39: 40424047, 1979.
  • 21
    Meyer JS, Friedman E, McCrate MM, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 18791886, 1983.
  • 22
    Olszewsky W, Darzynkiewicz Z, Claps ML, Melamed MR: Flow cytometry of lung carcinoma: A comparison of DNA stemline and cell cycle distribution with histology. Anal Quant Cytol 4: 9094, 1982.
  • 23
    Raber M, Barlogie B, Farquhar D: Determination of ploidy abnormality and cell cycle distribution in human lung cancer using DNA flow cytometry. Proc Am Assn Cancer Res 21: 40, 1980.
  • 24
    Sonka J, Stöhr M, Vogt-Schaden M, Volm M: Isopycnic density-gradient centrifugation: A separation parameter which improves flow cytometric measurements on heterogeneous tumours. Cytometry 4: 141149, 1983.
  • 25
    Straus MJ, Moran RE, Shackney SE: Growth characteristics of lung cancer. In: Lung Cancer: Clinical Diagnosis and Treatment, StrausMJ (ed). Grune Stratton, New York, 1983, p 21.
  • 26
    Teodori L, Tirindelli-Danesi D, Mauro F, DeVita R, Uccelli R, Botti C, Mondini C, Nervi C, Stipa S: Non-small cell lung carcinoma: Tumour characterization on the basis of flow cytometrically determined cellular heterogeneity. Cytometry 4: 174183, 1983.
  • 27
    Tubiana M, Pejovic MJ, Renaud A, Contesso G, Chavandra N, Gioanni J, Malaise EP: Kinetic parameters and the course of the disease in breast cancer. Cancer 47: 937943, 1981.
  • 28
    Vindeløv LL, Hansen HH, Christensen IJ, Spang-Thomsen M, Hirsch FR, Hansen M, Nissen NI: Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow cytometric DNA analysis. Cancer Res 40: 42954300, 1980.
  • 29
    Volm M, Wayss K, Kaufmann M, Mattern J: Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer 15: 983993, 1979.
  • 30
    Wolley RC, Schreiber K, Koss LG, Karas M, Sherman A: DNA distribution in human colon carcinomas and its relationship to clinical behaviour. J Natl Cancer Inst 69: 1522, 1982.
  • 31
    World Health Organization: Histological typing of lung tumours. Tumori 6: 253272, 1981.